Free Trial
NASDAQ:GRAL

GRAIL (GRAL) Stock Price, News & Analysis

GRAIL logo
$47.56 -1.67 (-3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$47.20 -0.36 (-0.75%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GRAIL Stock (NASDAQ:GRAL)

Key Stats

Today's Range
$45.37
$48.94
50-Day Range
$32.16
$51.42
52-Week Range
$12.33
$63.99
Volume
1.42 million shs
Average Volume
1.20 million shs
Market Capitalization
$1.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.50
Consensus Rating
Hold

Company Overview

GRAIL Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

GRAL MarketRank™: 

GRAIL scored higher than 11% of companies evaluated by MarketBeat, and ranked 883rd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GRAIL has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GRAIL has only been the subject of 1 research reports in the past 90 days.

  • Read more about GRAIL's stock forecast and price target.
  • Earnings Growth

    Earnings for GRAIL are expected to grow in the coming year, from ($15.15) to ($12.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GRAIL is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GRAIL is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GRAIL has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about GRAIL's valuation and earnings.
  • Percentage of Shares Shorted

    20.01% of the float of GRAIL has been sold short.
  • Short Interest Ratio / Days to Cover

    GRAIL has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in GRAIL has recently increased by 0.85%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    GRAIL does not currently pay a dividend.

  • Dividend Growth

    GRAIL does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.01% of the float of GRAIL has been sold short.
  • Short Interest Ratio / Days to Cover

    GRAIL has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in GRAIL has recently increased by 0.85%, indicating that investor sentiment is decreasing.
  • News Sentiment

    GRAIL has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for GRAIL this week, compared to 7 articles on an average week.
  • Search Interest

    Only 7 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,726,678.00 in company stock.

  • Read more about GRAIL's insider trading history.
Receive GRAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GRAIL and its competitors with MarketBeat's FREE daily newsletter.

GRAL Stock News Headlines

Top-Performing MedTech Stocks in 2025 - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
3 Medical Technology Stocks Outperforming in 2025 (GRAL)
Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
Trading up GRAIL sneakers at Sneaker Con
See More Headlines

GRAL Stock Analysis - Frequently Asked Questions

GRAIL's stock was trading at $17.85 on January 1st, 2025. Since then, GRAL shares have increased by 166.4% and is now trading at $47.56.
View the best growth stocks for 2025 here
.

GRAIL, Inc. (NASDAQ:GRAL) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($3.10) EPS for the quarter, topping analysts' consensus estimates of ($4.03) by $0.93. The firm earned $31.84 million during the quarter, compared to analyst estimates of $35.80 million. GRAIL had a negative net margin of 1,464.53% and a negative trailing twelve-month return on equity of 17.99%.
Read the conference call transcript
.

Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GRAIL investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
5/13/2025
Today
7/02/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Healthcare
Current Symbol
NASDAQ:GRAL
Previous Symbol
NASDAQ:GRAL
Web
N/A
Fax
N/A
Employees
1,360
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.50
High Stock Price Target
$43.00
Low Stock Price Target
$20.00
Potential Upside/Downside
-35.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.03 billion
Net Margins
-1,464.53%
Pretax Margin
-1,594.58%

Debt

Sales & Book Value

Annual Sales
$125.60 million
Cash Flow
$27.33 per share
Price / Cash Flow
1.78
Book Value
$74.50 per share
Price / Book
0.65

Miscellaneous

Free Float
N/A
Market Cap
$1.75 billion
Optionable
Optionable
Beta
N/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:GRAL) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners